Could a diabetes drug boost bariatric surgery results?

NCT ID NCT06721507

Recruiting now Disease control Sponsor: Marlene Starr Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking tirzepatide (Mounjaro/Zepbound) for three months before bariatric surgery reduces inflammation and leads to better weight loss and fewer complications. Fifty adults with obesity scheduled for surgery will either receive the drug or standard diet and lifestyle advice. Researchers will measure inflammatory markers in blood and tissue, and track weight and surgical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (also known as Mounjaro, Zepbound)
What this could lead to: If it works, this could point toward a standard approach of using tirzepatide before bariatric surgery to reduce inflammation and improve recovery and long-term health.
What could go wrong: This is a small early-phase trial with only 50 participants, so results may not apply to everyone. Tirzepatide can cause side effects like nausea and vomiting, and it is not yet known if it truly improves surgical outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARIATRIC SURGERY OBESITY AND OBESITY-RELATED MEDICAL CONDITIONS

Contacts and locations

Locations

University of Kentucky
RECRUITING

Lexington, Kentucky, 40506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.